KBKesavan Babu

Kesavan Babu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kesavan Babu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A New Perspective in Chemical Probe Discovery: Expanding Virtual Screening into Metal Complex Chemical Space

    by Mika Kintzel, Yew Mun Yip, Daniella Hares, Jonathan Bailey, Alain Oregioni, Sarah Maslen, Simone Kunzelmann, Kesavan Babu, Lygia Silva de Moraes, Luiz Pedro S . de Carvalho, et al.

    Transition metal complexes provide rigid, shape-defined molecular architectures in which the coordination geometry precisely organizes ligand functionality in three dimensions, making them attractive scaffolds for target-based chemical probe discovery. Yet, their broader and prospective use in structure-based virtual screening has remained largely unexplored, due to the absence of structurally diverse, computationally tractable screening libraries. Here, we address this by curating MOSAIC (Metal complex library for Structure-Aided In silico screening), a first collection of 16,901 neutral, drug-like metal complexes assembled directly from experimentally determined geometries deposited in the Cambridge Structural Database. Using MOSAIC , we perform a high-throughput virtual screening campaign against the allosteric pocket of methionine adenosyltransferase 2A (MAT2A), identifying the copper complex Cu1-Complex , for which nano differential scanning fluorimetry (nanoDSF) confirmed strong binding in vitro . The diamagnetic zinc analogue Zn1-Comple x allowed orthogonal binding characterization with ligand-observed and competition NMR studies. Along with Hydrogen–deuterium exchange mass spectrometry (HDX-MS), site-directed mutagenesis and molecular dynamics (MD), these studies show that Zn1-Complex engages the MAT2A through an allosteric pocket, inhibiting enzymatic activity. Together, this establishes MOSAIC as a scalable and generalizable virtual screening platform for transition metal complexes and demonstrates the potential of these metal-based scaffolds as chemical probes to uncover new modes of protein recognition.

  • Open Access

    Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code

    by Joseph E. McPherson, Molly S. Sneddon, Richard K. Begyinah, Kesavan Babu, Kerstin E. Peterson, Ryan F. Friess, Thomas G. Smith, Natalia Y. Tretyakova, Marcus Fischer, William C.K. Pomerantz

    Epigenetic readers are a class of proteins that recognize specific chemical modifications on histones to differentially regulate gene expression. Aberrant expression of readers can drive the progression of many diseases and cancers, making this protein class viable therapeutic targets. Understanding the landscape of histone modifications recognized by reader domains, and the structural mechanisms that drive these molecular recognition events, is crucial for guiding the design of pharmaceutically relevant chemical probes. BPTF contains a plant homeodomain (PHD) finger and tandem bromodomain (BRD). Here, we expand upon previous studies that found the BPTF BRD can engage acetyllysine modifications on the N-terminus of histone H3. We uncover H3K4me 3 K14ac as the specific modifications recognized by the PHD-BRD cassette, which is confirmed by crystallography. Using orthogonal methods, our work explores how these modifications can be read cooperatively, including in cis. We report the first experimental evidence proposing a ligand-induced conformational change between the two reader domains of BPTF, supporting previous computational approaches that have predicted a macromolecular rearrangement. We leverage these structural insights to rationally design a peptide-small molecule conjugate MJ-1 that inhibits both domains of BPTF and overcomes ligandability challenges associated with PHD-finger-containing proteins. The results presented here elucidate the molecular basis of the bivalent recognition of multiply modified histone H3 by BPTF and provide structural insight for developing compounds targeting the PHD finger of BPTF for therapeutic applications.

  • Open Access

    Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma

    by Kesavan Babu, Chun‐Ju Tsou, Sourav Das, Liying Fan, Anasuya Pal, Molly Sneddon, Timothy R. Stachowski, Priyanka Samanta, Stanley Nithianantham, Caroline Buchholz, et al.

    Bromodomain PHD finger Transcription Factor (BPTF) is an epigenetic regulator implicated in cancer progression. However, despite its oncogenic significance, highly selective and potent inhibitors of the BPTF bromodomain (BRD) with suitable physicochemical properties are lacking. Previously, we reported BZ1 , a submicromolar BPTF inhibitor that has off‐target activities. Here, we applied comparative structural biology and molecular modeling to design BZ2 , a regioisomer of BZ1 with enhanced selectivity for BPTF over other class I BRDs and class‐IV BRDs such as BRD7 and BRD9. Crystal structures and computational analyses reveal that differential engagement of water networks and polar interactions drives this selectivity. Functional studies demonstrate that genetic disruption of the BPTF BRD or treatment with BZ2 suppresses neuroblastoma (NB) cell growth. With high potency and improved physicochemical properties, BZ2 provides a valuable tool for probing the biology of BPTF and represents a promising starting point for advancing BPTF‐targeted drug development.


  • Open Access

    Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma

    by Kesavan Babu, Chun‐Ju Tsou, Sourav Das, Liying Fan, Anasuya Pal, Molly Sneddon, Timothy R. Stachowski, Priyanka Samanta, Stanley Nithianantham, Caroline Buchholz, et al.

    Bromodomain PHD finger Transcription Factor (BPTF) is an epigenetic regulator implicated in cancer progression. However, despite its oncogenic significance, highly selective and potent inhibitors of the BPTF bromodomain (BRD) with suitable physicochemical properties are lacking. Previously, we reported BZ1 , a submicromolar BPTF inhibitor that has off‐target activities. Here, we applied comparative structural biology and molecular modeling to design BZ2 , a regioisomer of BZ1 with enhanced selectivity for BPTF over other class I BRDs and class‐IV BRDs such as BRD7 and BRD9. Crystal structures and computational analyses reveal that differential engagement of water networks and polar interactions drives this selectivity. Functional studies demonstrate that genetic disruption of the BPTF BRD or treatment with BZ2 suppresses neuroblastoma (NB) cell growth. With high potency and improved physicochemical properties, BZ2 provides a valuable tool for probing the biology of BPTF and represents a promising starting point for advancing BPTF‐targeted drug development.

  • Open Access

    Expanding Metal Complex Enzyme Inhibitor Discovery Through High-Throughput Virtual Screening

    by Mika Kintzel, Yew Mun Yip, Daniella Hares, Jonathan Bailey, Alain Oregioni, Sarah Maslen, Simone Kunzelmann, Kesavan Babu, Lygia Silva de Moraes, Luiz Pedro S . de Carvalho, et al.

    Transition metal complexes occupy regions of three-dimensional chemical space that organic scaffolds cannot easily reach, yet their use in target-based drug discovery has been held back by the absence of structurally diverse, readily available screening libraries. We addressed this by curating MOSAIC ( M etal c o mplex library for S tructure- Ai ded I n silico s c reening), a first collection of 16,901 neutral, drug-like metal complexes assembled directly from experimentally determined geometries deposited in the Cambridge Structural Database. Docking this library against the allosteric site of the oncology target MAT2A (methionine adenosyltransferase 2A) with MetalDock returned the copper complex Cu1-Complex , from which we designed the diamagnetic zinc analogue Zn1-Complex for detailed study. A combination of nanoDSF, ligand-observed and competition NMR, HDX-MS, site-directed mutagenesis and molecular dynamics placed Zn1-Complex in the allosteric pocket and showed that it engages the site differently from the established inhibitor Pf-9366 , while functionally inhibiting the enzyme. Together, these results establish MOSAIC as a validated, generalisable platform for target-based metal complex discovery as the first scalable strategy for systematically exploiting metal complexes against any well-defined binding site.

  • Open Access

    Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma

    by Kesavan Babu, Chun-Ju Tsou, Sourav Das, Liying Fan, Molly Sneddon, Timothy R. Stachowski, Priyanka Samantha, Stanley Nithianantham, Anasuya Pal, Caroline Buchholz, et al.

    Bromodomain PHD finger Transcription Factor (BPTF) is an epigenetic regulator implicated in cancer progression. However, despite its oncogenic significance, highly selective and potent inhibitors of the BPTF bromodomain (BRD) with suitable physicochemical properties are lacking. Previously, we reported BZ1, a submicromolar BPTF inhibitor which has off-target activities. Here, we applied comparative structural biology and molecular modeling to design BZ2, a regioisomer of BZ1 with enhanced selectivity for BPTF over other class I bromodomains and class-IV BRDs such as BRD7 and BRD9. Co-crystal structures and computational analyses reveal that differential engagement of water networks and polar interactions drives this selectivity. Functional studies demonstrate that genetic disruption of the BPTF BRD or treatment with BZ2 suppresses neuroblastoma cell growth. With high potency and improved physicochemical properties, BZ2 provides a valuable tool for probing the biology of BPTF and represents a promising starting point for advancing BPTF-targeted drug development.

  • Open Access

    Role Of Bridge Helix In Mediating DNA Recognition And Efficient Cleavage By CRISPR‐ Cas12a

    by Hari Priya Parameshwaran, Kesavan Babu, Lindsie Martin, Christine Tran, Aleiqué Allen, Peter Qin, Rakhi Rajan

    Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‐associated (Cas) proteins are adaptive immune systems in bacteria and archaea. They utilize CRISPR RNA (crRNA) molecules to guide Cas nucleases to cleave invading foreign DNA and/or RNA, in a sequence specific manner. Of the several different types, Cas9 of type II and Cas12a of type V CRISPR‐Cas systems are most commonly used for gene editing since they are both single, multi‐domain polypeptides, which when equipped with a guide‐RNA can bind and cleave DNA, sequence specifically. Bridge helix (BH) is a highly conserved arginine‐rich helix present in several Cas proteins and is indispensable for protein function. We previously established that BH imparts selectivity in cleaving target DNA in Cas9 from Streptococcus pyogenes (SpyCas9). Substitution of two residues within the BH with prolines resulted in a variant (SpyCas9 2Pro ), which showed significant reduction in cleavage when targets had mismatches closer to the Cas9‐cleavage site. Due to conservation of BH, we hypothesized that a similar DNA mismatch selectivity may be present in Cas12a as well. We tested Cas12a from Francisella novicida (FnoCas12a) by introducing proline substitution in its BH, creating a variant (FnoCas12a KD2P ). During RNA‐dependent DNA cleavage ( cis cleavage), FnoCas12a KD2P discriminated against mismatch‐containing supercoiled DNA substrates causing reduction in double‐stranded DNA break resulting in accumulation of nicked products, a phenomenon that was observed in SpyCas9 2Pro as well. BH also provided the ability for Cas12a to cleave different physical forms of DNA such as single/double, superhelical/linear. Additionally, we also observed that the BH plays a significant role in efficiency of trans cleavage, a promiscuous ssDNA cleavage activity of Cas12a proteins, that is activated upon cis ‐DNA binding. Current studies include characterizing other Cas12a variants to understand the comprehensive role of BH in Cas protein function. These results implicate that in addition to the previously observed mismatch selectivity imparted by BH, it contributes to substrate preferences and other forms of DNA cleavage catalyzed by Cas proteins. Our results form a framework that can be adapted to modify DNA cleavage selectivity of several BH‐containing Cas proteins, by modulating BH, which will enable creation of high‐fidelity Cas protein variants for gene editing applications.